[
    [
        {
            "time": "2018-01-30",
            "original_text": "Sanofi on a Buyout Spree This Month, to Buy Ablynx for $4.8B",
            "features": {
                "keywords": [
                    "Sanofi",
                    "Buyout",
                    "Ablynx",
                    "4.8B"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Sanofi on a Buyout Spree This Month, to Buy Ablynx for $4.8B",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-30",
            "original_text": "Can Merck (MRK) Deliver a Positive Surprise in Q4 Earnings?",
            "features": {
                "keywords": [
                    "Merck",
                    "Q4",
                    "Earnings",
                    "Positive",
                    "Surprise"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Can Merck (MRK) Deliver a Positive Surprise in Q4 Earnings?",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-30",
            "original_text": "Why Novo Nordisk (NVO) Might Surprise This Earnings Season",
            "features": {
                "keywords": [
                    "Novo",
                    "Nordisk",
                    "Earnings",
                    "Season",
                    "Surprise"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Why Novo Nordisk (NVO) Might Surprise This Earnings Season",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-30",
            "original_text": "Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom",
            "features": {
                "keywords": [
                    "Sanofi",
                    "Novo",
                    "Ablynx",
                    "4.8",
                    "billion",
                    "biotech",
                    "M&A"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 10,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 9,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        }
    ]
]